氯胺酮对比依托咪酯用于快速序贯插管:随机试验的系统评价与荟萃分析
该系统评价与荟萃分析检索了MEDLINE、Embase、Cochrane临床试验注册库和ClinicalTrials.gov(自建库至2024年4月3日),纳入7项比较氯胺酮与依托咪酯用于成人急诊气管插管的随机对照试验(n=2384例)。汇总分析显示,与依托咪酯相比,氯胺酮可能增加围插管期血流动力学不稳定(RR 1.29;95%CI 1.07-1.57;中等确定性),但可能减少持续泵入升压药的启动需求(RR 0.75;95%CI 0.57-1.00;中等确定性)并减轻肾上腺抑制(RR 0.54;95%CI 0.45-0.66;中等确定性)。氯胺酮对首次插管成功率(RR 1.01;95%CI 0.97-1.05;中等确定性)、ICU最初3天内最大SOFA评分(平均差低0.55分;95%CI 低1.12至升高0.03;中等确定性)可能无影响,对死亡率可能无影响(RR 1.00;95%CI 0.83-1.21;低确定性)。
要点
- 与依托咪酯相比,氯胺酮可能增加围插管期血流动力学不稳定(RR 1.29;95%CI 1.07-1.57;中等确定性)。
- 氯胺酮可能减少持续泵入升压药的启动需求(RR 0.75;95%CI 0.57-1.00;中等确定性),并减轻肾上腺抑制(RR 0.54;95%CI 0.45-0.66;中等确定性)。
- 氯胺酮对首次插管成功率可能无影响(RR 1.01;95%CI 0.97-1.05;中等确定性),对死亡率可能无影响(RR 1.00;95%CI 0.83-1.21;低确定性)。
- 氯胺酮对ICU最初3天内最大SOFA评分可能无影响(平均差低0.55分;95%CI 低1.12至升高0.03;中等确定性)。
适用人群与场景
- 成人急诊气管插管患者(纳入随机对照试验比较氯胺酮与依托咪酯用于急诊气管插管)。
研究设计与关键结果
- 系统评价与荟萃分析,纳入7项随机对照试验(n=2384例患者),检索MEDLINE、Embase、Cochrane临床试验注册库和ClinicalTrials.gov自建库至2024年4月3日。
- 与依托咪酯相比,氯胺酮可能增加围插管期血流动力学不稳定(RR 1.29;95%CI 1.07-1.57;中等确定性)。
- 与依托咪酯相比,氯胺酮可能减少持续泵入升压药的启动需求(RR 0.75;95%CI 0.57-1.00;中等确定性)。
- 与依托咪酯相比,氯胺酮可能减轻肾上腺抑制(RR 0.54;95%CI 0.45-0.66;中等确定性)。
- 与依托咪酯相比,氯胺酮对首次插管成功率可能无影响(RR 1.01;95%CI 0.97-1.05;中等确定性)。
- 与依托咪酯相比,氯胺酮对ICU最初3天内最大SOFA评分可能无影响(平均差低0.55分;95%CI 低1.12至升高0.03;中等确定性)。
- 与依托咪酯相比,氯胺酮对死亡率可能无影响(RR 1.00;95%CI 0.83-1.21;低确定性)。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与荟萃分析;采用GRADE方法评估证据确定性,结果中报告了中等确定性和低确定性。
- 局限:原文未报告局限性。
对床旁实践的改变
- 与依托咪酯相比,氯胺酮可能增加围插管期血流动力学不稳定,但可能减少持续泵入升压药的启动需求并减轻肾上腺抑制;对首次插管成功率和死亡率可能无影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To compare the safety and efficacy of ketamine and etomidate as induction agents to facilitate emergent endotracheal intubation.
DATA SOURCES: We searched MEDLINE, Embase, Cochrane Clinical Trials Register, and ClinicalTrials.gov from inception to April 3, 2024.
STUDY SELECTION: We included randomized controlled trials (RCTs) that compared ketamine to etomidate to facilitate emergent endotracheal intubation in adults.
DATA EXTRACTION: Reviewers screened abstracts, full texts, and extracted data independently and in duplicate. We pooled data using a random-effects model, assessed risk of bias using the modified Cochrane tool and certainty of evidence using the Grading Recommendations Assessment, Development, and Evaluation approach. We pre-registered the protocol on PROSPERO (CRD42023472450).
DATA SYNTHESIS: We included seven RCTs ( n = 2384 patients). Based on pooled analysis, compared with etomidate, ketamine probably increases hemodynamic instability in the peri-intubation period (relative risk [RR], 1.29; 95% CI, 1.07-1.57; moderate certainty) but probably decreases the need for initiation of continuous infusion vasopressors (RR, 0.75; 95% CI, 0.57-1.00; moderate certainty) and results in less adrenal suppression (RR, 0.54; 95% CI, 0.45-0.66; moderate certainty). Ketamine probably has no effect on successful intubation on the first attempt (RR, 1.01; 95% CI, 0.97-1.05; moderate certainty) or organ dysfunction measured as the maximum Sequential Organ Failure Assessment (SOFA) score during the first 3 days in ICU (mean difference, 0.55 SOFA points lower; 95% CI, 1.12 lower to 0.03 higher; moderate certainty) and may have no effect on mortality (RR, 1.00; 95% CI, 0.83-1.21; low certainty) when compared with etomidate.
CONCLUSIONS: Compared with etomidate, ketamine probably results in more hemodynamic instability during the peri-intubation period and appears to have no effect on successful intubation on the first attempt or mortality. However, ketamine results in decreased need for the initiation of vasopressor use and decreases adrenal suppression compared with etomidate.
参考来源
- Greer A, Hewitt M, Khazaneh PT, et al. Ketamine Versus Etomidate for Rapid Sequence Intubation: A Systematic Review and Meta-Analysis of Randomized Trials. Crit Care Med. 2024. PMID: 39570063. doi:10.1097/CCM.0000000000006515
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。